Welcome to the Legend Biotech’s First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer ...

Poster presentation to demonstrate EBT-107's potential to reduce clinically-relevant biomarkers and HBV DNA integration toward functiona ...

Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart DiseaseSOUTH SAN FRANCISCO, Calif., May ...

Data support planned dosing regimen and protocol for FIH study to initiate in mid-2025 LONDON, May 13, 2025 (GLOBE NEWSWIRE) ...

"The data we will present at ASGCT underscore the power and versatility of Encoded's vector engineering platform to target a wide array of validated disease pathways with potential one-time treatments ...

Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today presents IND- and CTA-enabling data for its lead clinical program, ...

Cash: As of March 31, 2025, Cellectis had $246 million in consolidated cash, cash equivalents, restricted cash and fixed-term ...

Siren Biotechnology Inc., pioneers of Universal AAV Immuno-Gene Therapy for Cancer, today announced that it will present new ...